NeuroBo Pharmaceuticals, Inc.(NASDAQ : NRBO)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|SNSS||Sunesis Pharmaceuticals, Inc.||-2.32%||10.52||0.7%||$735.39m|
|VRTX||Vertex Pharmaceuticals, Inc.||0.60%||201.58||1.9%||$414.73m|
|GILD||Gilead Sciences, Inc.||-2.21%||68.29||1.0%||$401.30m|
|REGN||Regeneron Pharmaceuticals, Inc.||-1.46%||574.61||2.7%||$353.89m|
|NTLA||Intellia Therapeutics, Inc.||3.53%||141.85||2.3%||$263.90m|
|CRSP||CRISPR Therapeutics AG||1.70%||121.02||0.6%||$144.72m|
|EXAS||EXACT Sciences Corp.||-3.64%||107.84||18.1%||$123.59m|
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline include ANA001, a proprietary oral niclosamide formulation; Gemcabene, which is assessed as an acute indication for COVID-19; NB-01, a treatment for painful diabetic neuropathy; and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases. The company was founded on October 30, 2014 and is headquartered in Boston, MA.